Table 5.
Postoperative drug therapy.
| Author, year | Age | ER, PR | Name of drug | Dose | Course of treatment | Follow-up result |
|---|---|---|---|---|---|---|
| Shinohara 2004 (20) | 34 | ER (+), PR (+) | GnRH-a | NA | 12 months | Recurrence, 3 months after drug withdrawal |
| Alobaid 2005 (24) | 30 | ER (+), PR (+) | GnRH-a | Once every other month | 6 months | No recurrence in 9 months |
| Hidalgo-Zambrano 2020 (59) | 46 | ER (+), PR: NA | GnRH-a | NA | NA | NA |
| Xu 2020 (62) | 25 | ER (+), PR (+) | GnRH-a | 3.75 mg/month | 3 months | No recurrence in 9 months |
| Akhavan 2021 (63) | 33 | NA | GnRH-a | NA | NA | No recurrence in 6 months |
| Elsaqa 2022 (72) | 40 | ER (+), PR: NA | GnRH-a | NA | NA | No recurrence in 6 months |
| Goyal 2022 (74) | 40 | ER (+), PR (+) | GnRH-a | 3.75 mg/month | 3 months | No recurrence in 1 year |
| Narang 2022 (76) | 18 | ER (+), PR (+) | GnRH-a | 12.5 mg/3 month | 2 years | No recurrence in 1 year |
| Husso 2017 (50) | 61 | No recurrence in 18 months | ||||
| Peterknecht 2021 (67) | 65 | ER (+), PR (+) | Letrozole | NA | NA | NA |
| Herrera-Castro 2017 (49) | 39 | ER (+), PR (+) | Tamoxifen | NA | NA | NA |
| Srivastava 2021 (68) | 37 | ER (+), PR (+) | Tamoxifen | 20 mg/day | NA | No recurrence in 2 years |
| Abu 2005 (23) | 46 | ER (+), PR (+) | Raloxifene | NA | NA | NA |
| Palomba 2011 (36) | 32 | ER (+), PR (+) | GnRH-a + Raloxifene | GnRH-a: 3.75 mg/28 days, Raloxifene: 180 mg/day | NA | No recurrence in 2 years |
| Zamani 2021 (70) | 28 | NA | Decapeptide | NA | NA | NA |
NA, not available.